Telix Pharmaceuticals Ltd. (AU:TLX)
ASX:TLX
TLX Stock Chart & Stats
AU$12.95
-AU$0.59(-2.38%)
At close: 4:00 PM EST
AU$12.95
-AU$0.59(-2.38%)
Day’s Range― - ―
52-Week RangeAU$8.26 - AU$29.64
Previous CloseN/A
Volume456.62K
Average Volume (3M)3.35M
Market Cap
AU$4.39B
Enterprise ValueAU$4.96B
Total Cash (Recent Filing)AU$212.74M
Total Debt (Recent Filing)AU$785.24M
Price to Earnings (P/E)―
Beta0.91
Next Earnings
Aug 20, 2026EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding338,891,050
10 Day Avg. Volume3,089,454
30 Day Avg. Volume3,348,061
Financial Highlights & Ratios
PEG Ratio2.81
Price to Book (P/B)6.08
Price to Sales (P/S)3.04
P/FCF Ratio-44.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$24.11Price Target Upside86.21% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)0.03
Revenue Forecast (FY)AU$959.10M
Bulls Say, Bears Say
Bulls Say
Diagnostics Strategy And Market AccessAnalyst's recommendation notes the two-product PSMA PET diagnostic strategy can broaden market access by appealing to payors with different reimbursement preferences.
Regulatory Catalyst — Pixclara ResubmissionAnticipated resubmission of the brain imaging agent Pixclara to the FDA is viewed as a potential catalyst toward US regulatory approval and would expand the US commercial portfolio if approved.
Revenue Reinvestment And Pipeline FundingCompany pre-reported diagnostic-driven revenue growth is expected to be reinvested into a therapeutics pipeline led by three pivotal programs, supporting further drug development.
Bears Say
Legacy Product Sales WeaknessAnalyst's report highlights softness in legacy RLS products, creating a headwind to overall revenue growth.
Potential Conflicts Affecting Report ObjectivityDisclosure that the publishing firm may have business relationships with covered companies raises concerns about conflicts that could affect report objectivity and investor confidence.
Valuation And Price Target ReductionReduction of the price target signals tempered expectations for the company's valuation and may pressure investor sentiment.
Telix Pharmaceuticals News
TLX FAQ
What was Telix Pharmaceuticals Ltd.’s price range in the past 12 months?
Telix Pharmaceuticals Ltd. lowest share price was AU$8.26 and its highest was AU$29.64 in the past 12 months.
What is Telix Pharmaceuticals Ltd.’s market cap?
Telix Pharmaceuticals Ltd.’s market cap is AU$4.39B.
When is Telix Pharmaceuticals Ltd.’s upcoming earnings report date?
Telix Pharmaceuticals Ltd.’s upcoming earnings report date is Aug 20, 2026 which is in 136 days.
How were Telix Pharmaceuticals Ltd.’s earnings last quarter?
Telix Pharmaceuticals Ltd. released its earnings results on Feb 19, 2026. The company reported -AU$0.017 earnings per share for the quarter, missing the consensus estimate of AU$0.057 by -AU$0.074.
Is Telix Pharmaceuticals Ltd. overvalued?
According to Wall Street analysts Telix Pharmaceuticals Ltd.’s price is currently Undervalued.
Does Telix Pharmaceuticals Ltd. pay dividends?
Telix Pharmaceuticals Ltd. does not currently pay dividends.
What is Telix Pharmaceuticals Ltd.’s EPS estimate?
Telix Pharmaceuticals Ltd.’s EPS estimate is 0.02.
How many shares outstanding does Telix Pharmaceuticals Ltd. have?
Telix Pharmaceuticals Ltd. has 338,891,050 shares outstanding.
What happened to Telix Pharmaceuticals Ltd.’s price movement after its last earnings report?
Telix Pharmaceuticals Ltd. reported an EPS of -AU$0.017 in its last earnings report, missing expectations of AU$0.057. Following the earnings report the stock price went up 14.239%.
Which hedge fund is a major shareholder of Telix Pharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in AU:TLX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Telix Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
AU$24.11 (86.21% Upside)
AU$24.11 (86.21% Upside)
Blogger Sentiment
Bullish
AU:TLX Sentiment 92%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-43.73%
12-Months-Change
Fundamentals
Return on Equity
-2.08%
Trailing 12-Months
Asset Growth
25.10%
Trailing 12-Months
Company Description
Telix Pharmaceuticals Ltd.
Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation (MTR) products for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company focuses on developing diagnostic and therapeutic products using MTR. Its lead products include TLX591-CDx for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX250-CDx that is in Phase III clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX591, which is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX101 that is in Phase I/II clinical trials and TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); and TLX66, which is in Phase I/IIa clinical trials for the treatment of bone marrow conditioning and rare diseases. The company also develops TLX592, a prostate cancer therapy candidate for targeted alpha therapy; TLX591-Sx, a positron emission tomography (PET) tracer that delivers PET and fluorescent (optical) imaging; and TLX599-CDx, an investigational prostate cancer imaging agent that uses single photon emission computed tomography. It has a strategic license and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited for developing a portfolio of MTR products; scientific and clinical research collaboration with Mauna Kea Technologies; and strategic collaboration agreement with Lightpoint Medical, Ltd. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
TLX Company Deck
TLX Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a predominantly positive commercial and strategic picture: very strong top-line growth (56% FY2025), a high-margin, cash-generative Precision Medicine engine, successful recent FDA approval and launches, a deep late-stage pipeline with three pivotal therapeutic programs, and upgraded R&D investment to accelerate therapeutics. Offsetting these strengths are regulatory setbacks that require resubmissions (Pixclara and Zircaix), modest consolidated profitability due to aggressive reinvestment (adjusted EBITDA $39.5M), a lean year-end cash balance after major investments, and near-term concentration in the U.S. reimbursement environment. Management has outlined a clear plan to self-fund pipeline advancement and scale manufacturing, but execution and timing of regulatory approvals and the ramp of international reimbursement remain key risks.View all AU:TLX earnings summariesTLX Stock 12 Month Forecast
Average Price Target
AU$24.11
▲(86.21% Upside)
Technical Analysis
Imugene
―
Immutep Ltd
―
Race Oncology Ltd.
―
Clarity Pharmaceuticals Ltd.
―
Radiopharm Theranostics Limited
―
Options Prices
Currently, No data available
---